-20.3%
RIOT vs MRNA
+945.0%
-965.3%
-58.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +9.6% | +13.1% | -3.5% | +8.8% |
| 7D | +6.4% | +20.6% | -14.3% | +5.2% |
| 30D | -20.4% | +27.1% | -47.6% | -21.5% |
| 3M | -28.7% | +353.4% | -382.1% | -39.7% |
| 6M | -17.7% | +446.3% | -464.0% | -38.2% |
| YTD | +21.3% | +776.2% | -754.9% | -25.6% |
| 1Y | -20.3% | +987.9% | -1,008.2% | -54.9% |
| All | -20.3% | +945.0% | -965.3% | -54.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling